aTyr Pharma (FRA:471A) Change In Receivables : €-0.36 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is aTyr Pharma Change In Receivables?

aTyr Pharma's change in receivables for the quarter that ended in Mar. 2024 was €0.42 Mil. It means aTyr Pharma's Accounts Receivable declined by €0.42 Mil from Dec. 2023 to Mar. 2024 .

aTyr Pharma's change in receivables for the fiscal year that ended in Dec. 2023 was €8.30 Mil. It means aTyr Pharma's Accounts Receivable declined by €8.30 Mil from Dec. 2022 to Dec. 2023 .

aTyr Pharma's Accounts Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. aTyr Pharma's Days Sales Outstanding for the three months ended in Mar. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. aTyr Pharma's liquidation value for the three months ended in Mar. 2024 was €51.09 Mil.

aTyr Pharma Change In Receivables Historical Data

The historical data trend for aTyr Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

aTyr Pharma Change In Receivables Chart

aTyr Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

0.05

-1.59

1.42

-11.26

8.30

aTyr Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															9.23	0.62	-0.98	-0.42	0.42

aTyr Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.36 Mil.

aTyr Pharma (FRA:471A) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

aTyr Pharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.216	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, aTyr Pharma's accounts receivable are only considered to be worth 75% of book value:

aTyr Pharma's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	77.736	-	26.651	+	0.75 * 0	+	0.5 * 0
=	51.09

aTyr Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of aTyr Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

aTyr Pharma (FRA:471A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (FRA:471A) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

LIFE:USA

Address

10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121

Website

https://www.atyrpharma.com

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

aTyr Pharma (FRA:471A) Headlines

No Headlines